Medical research and development contract DHA sbir phase II proposal no. H2S-0005 titled development of an effective adsorber to remove anti-a and anti-b antibodies from plasma for transfusion.
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH20C0087
- Awardee
-
Cytosorbents Medical Inc. UEI LSF2KFUSY4K7 Part of Cytosorbents Corporation
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $1,098,589
Award facts
- Contract value 100% obligated
- $1,098,588.51 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AN91 R&D- Medical: Other (Basic Research)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Monmouth Junction, South Brunswick Township, NJ 08852, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,098,589 |
About this award
This $1.1 million firm fixed price contract was awarded by the Department of the Army Medical Command to Cytosorbents Medical Inc., doing business as Cytosorbents, to support research and development of an adsorber to remove anti-A and anti-B antibodies from plasma for transfusion under the Small Business Innovation Research (SBIR) Program Phase II solicitation. As a total small business set-aside, the contract aims to further the prime contractor's development of an effective adsorber that can remove these antibodies from plasma to make it safer for transfusion, as requested in the Phase II proposal. Work will be performed by Cytosorbents Medical in Monmouth Junction, New Jersey through January 2024. The Department of the Army Medical Command seeks medical technologies to support soldiers through its research programs.
Quick answers
Who was awarded contract W81XWH20C0087?
W81XWH20C0087 was awarded to Cytosorbents Medical Inc. by Medical Command (Department of the Army) on September 24, 2020.
How much is contract W81XWH20C0087 worth?
The government has obligated $1,098,589 on W81XWH20C0087.
Was contract W81XWH20C0087 competed?
The extent of competition for W81XWH20C0087 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award